SELLAS Life Sciences (SLS) EBIT Margin (2012 - 2022)
SELLAS Life Sciences' (SLS) quarterly EBIT Margin came in at 1673.5% in Q1 2022, down 163411.0% year-on-year from N/an in Q1 2021, and down 614.05% on a QoQ basis from 234.37% in Q2 2021.
SELLAS Life Sciences (SLS) EBIT Margin (2012 - 2022) Analysis & Trends
SELLAS Life Sciences (SLS) has 7 years of EBIT Margin data on file, last reported at 1673.5% in Q1 2022.
- On a quarterly basis, EBIT Margin fell 163411.0% year-over-year to 1673.5% in Q1 2022; TTM through Dec 2022 was 4195.0%, a 386218.0% decrease from a year earlier, with the FY2022 full-year figure at 4195.0%, down 386218.0% from the prior year.
- EBIT Margin for Q1 2022 stood at 1673.5%, down from 234.37% in the prior quarter.
- Over the last five years, EBIT Margin for SLS reached as high as 39.39% in Q1 2021 and fell as low as 1673.5% in Q1 2022.
- Historically, EBIT Margin has averaged 541.54% across 3 years, with a median of 226.63% in 2021.
- On a YoY basis, EBIT Margin climbed as much as 163411 bps in 2022 and fell as far as 163411 bps in 2022.
- Year by year, EBIT Margin stood at 218.89% in 2020, then dropped by 7 bps to 234.37% in 2021, then tumbled by 614 bps to 1673.5% in 2022.
- Per Business Quant data, the three most recent EBIT Margin figures were 1673.5% in Q1 2022, 234.37% in Q2 2021, and 39.39% in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.96 Bn | 1.96 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -1,673.50% |
| Jun 30, 2021 | -234.37% |
| Mar 31, 2021 | -39.39% |
| Dec 31, 2020 | -218.89% |
| Jun 30, 2015 | -268.57% |
| Mar 31, 2015 | -324.07% |
| Dec 31, 2014 | -303.38% |
| Sep 30, 2014 | -652.28% |
| Jun 30, 2014 | -677.09% |
| Mar 31, 2014 | -545.28% |
| Dec 31, 2013 | -219.06% |
| Sep 30, 2013 | -425.49% |
| Jun 30, 2013 | -342.60% |
| Mar 31, 2013 | -304.23% |
| Dec 31, 2012 | 476.75% |
| Sep 30, 2012 | -472.48% |